BOL DP o 04
Alternative Names: BOLDPo 04Latest Information Update: 28 Jul 2024
At a glance
- Originator BOL Pharma
- Class Analgesics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pain
- No development reported Diabetic neuropathies
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Pain(In volunteers) in Israel (Sublingual, Tablet)
- 24 Oct 2022 Breath of Life International Pharma completes phase I trial in Healthy volunteers in Israel (Sublingual, Drops, Tablets) (NCT04261166)
- 26 Jul 2022 BOL DP o 04 is still in phase I/II trials for Pain in Israel (Sublingual) (NCT04145310)